Boehringer Ingelheim Pharmaceuticals, Inc. is pleased to announce that the U.S. Food and Drug Administration has granted approval for the launch of the all-new Cyltezo Pen. This novel autoinjector is Interchangeable with Humira® (adalimumab) and approved to treat multiple chronic inflammatory diseases.
Starting July 1, 2023, Cyltezo Pen will be available in 40 mg/0.8 mL pre-filled syringes in two-, four- and six-pack options – providing an easy and convenient way to effectively manage chronic inflammatory diseases.
Patients living with chronic inflammatory diseases now have an exciting new option to manage their conditions with the FDA approval of the Cyltezo Pen. This autoinjector offers an easy and convenient way to administer the medication they need, and launches July 1! Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim, is thrilled to be able to provide this additional option to those in need and looks forward to its launch.
The innovative Cyltezo Pen makes administering medications easy and stress-free! Featuring a single-button, three-step activation process and total drug visibility, this pen has been certified by the Arthritis Foundation as an “Ease of Use” product. With a protected needle, you can trust that your medication is administered safely and efficiently. Get your hands on this revolutionary design today to make your medication administration a breeze!
About Biosimilars
Biosimilars are revolutionizing the biopharmaceutical industry. These are biologic medications that are developed by a different company than the inventors, yet offer the same safe, potent and pure experience. Such game-changing medicines are transforming healthcare and giving consumers access to more cost-effective treatment options.
Patients who need biologics can now benefit from biosimilars, thanks to the FDA’s designation of interchangeable biologics. These interchangeable copies meet the same exacting standards as their reference products and even undergo an additional switching study in which patients are moved back-and-forth several times to prove safety and effectiveness. Depending on each state’s laws, providers and patients may be required to get notified when an interchangeble biosimilar is substituted.
About Boehringer Ingelheim in Biologics and Biosimilars
We are dedicated to providing safe and effective therapeutic solutions to patients around the world. Our unique array of biologics and interchangeable biosimilars make it possible for us to offer high-quality treatment options that can make a real difference in people’s lives. With our cutting-edge therapies, we are proud to expand access to powerful medicine and healthier futures.
Boehringer Ingelheim is a global pioneer in the production of biologic medicines. As one of the largest producers of biologics in the world, they have been helping customers bring dozens of biologics to the market since their inception. Their biologic medicines cover therapeutic areas such as oncology, immunology and cardiovascular indications, and they also provide contract manufacturing services to other companies for their biopharmaceuticals. Discover the power of Boehringer Ingelheim’s biopharma and manufacturing capabilities today